

# Dora Hammerl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10212948/publications.pdf>

Version: 2024-02-01

9  
papers

191  
citations

1684188

5  
h-index

1872680

6  
g-index

9  
all docs

9  
docs citations

9  
times ranked

285  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer germline antigens and tumor-agnostic CD8+ T cell evasion. Trends in Immunology, 2022, 43, 391-403.	6.8	6
2	V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. Cancers, 2021, 13, 2219.	3.7	7
3	Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. Biology, 2021, 10, 768.	2.8	1
4	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nature Communications, 2021, 12, 5668.	12.8	91
5	Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. Clinical Cancer Research, 2020, 26, 505-517.	7.0	26
6	Orthotopic editing of T-cell receptors. Nature Biomedical Engineering, 2019, 3, 949-950.	22.5	0
7	Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. Modern Pathology, 2018, 31, 1012-1025.	5.5	25
8	Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies. Trends in Immunology, 2018, 39, 921-936.	6.8	35
9	Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells. Blood, 2018, 132, 241-241.	1.4	0